CymaBay Therapeutics Inc. | Mutual Funds
Mutual Funds that own CymaBay Therapeutics Inc.
Vanguard Total Stock Market Index Fund
1,405,819
2.38%
0
0%
07/31/2018
Eagle Small Cap Growth Fund
1,349,044
2.27%
1,349,044
0.32%
06/29/2018
iShares Russell 2000 ETF
1,233,129
2.09%
-660
0.04%
09/06/2018
FTIF SICAV - Franklin Biotechnology Discovery Fund
1,120,400
1.9%
0
0.66%
06/30/2018
Vanguard Extended Market Index Fund
779,859
1.32%
5,900
0.02%
07/31/2018
Fidelity Select Biotechnology Portfolio
777,600
1.32%
-141,600
0.12%
07/31/2018
Candriam Equities L - Biotechnology
723,000
1.22%
353,000
0.73%
07/31/2018
Franklin Biotechnology Discovery Fund
678,300
1.14%
131,100
0.64%
03/31/2018
iShares Russell 2000 Growth ETF
431,125
0.73%
0
0.05%
09/06/2018
Fidelity Health Care Central Investment Portfolio
396,200
0.67%
396,200
0.17%
03/31/2018
| Address |
7575 Gateway Boulevard
Newark California 94560
United States
|
|
Employees
|
- |
| Website |
http://www.cymabay.com |
| Updated |
07/08/2019 |
| CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of biopharmaceutical products. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. |
